Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $79.62 billion. The enterprise value is $63.17 billion.
| Market Cap | 79.62B |
| Enterprise Value | 63.17B |
Important Dates
The next estimated earnings date is Tuesday, February 3, 2026, before market open.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Nov 20, 2025 |
Share Statistics
REGN has 102.60 million shares outstanding. The number of shares has decreased by -4.39% in one year.
| Current Share Class | 100.78M |
| Shares Outstanding | 102.60M |
| Shares Change (YoY) | -4.39% |
| Shares Change (QoQ) | -1.29% |
| Owned by Insiders (%) | 3.80% |
| Owned by Institutions (%) | 87.48% |
| Float | 98.52M |
Valuation Ratios
The trailing PE ratio is 18.68 and the forward PE ratio is 17.23. REGN's PEG ratio is 2.39.
| PE Ratio | 18.68 |
| Forward PE | 17.23 |
| PS Ratio | 5.73 |
| Forward PS | 5.22 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | 18.76 |
| P/OCF Ratio | 15.62 |
| PEG Ratio | 2.39 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.53, with an EV/FCF ratio of 14.96.
| EV / Earnings | 13.80 |
| EV / Sales | 4.43 |
| EV / EBITDA | 14.53 |
| EV / EBIT | 16.52 |
| EV / FCF | 14.96 |
Financial Position
The company has a current ratio of 4.06, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.06 |
| Quick Ratio | 3.19 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 0.64 |
| Interest Coverage | 90.81 |
Financial Efficiency
Return on equity (ROE) is 15.19% and return on invested capital (ROIC) is 7.27%.
| Return on Equity (ROE) | 15.19% |
| Return on Assets (ROA) | 6.16% |
| Return on Invested Capital (ROIC) | 7.27% |
| Return on Capital Employed (ROCE) | 10.70% |
| Revenue Per Employee | $943,188 |
| Profits Per Employee | $303,058 |
| Employee Count | 15,106 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.46 |
Taxes
In the past 12 months, REGN has paid $567.10 million in taxes.
| Income Tax | 567.10M |
| Effective Tax Rate | 11.02% |
Stock Price Statistics
The stock price has increased by +8.02% in the last 52 weeks. The beta is 0.37, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +8.02% |
| 50-Day Moving Average | 711.11 |
| 200-Day Moving Average | 604.30 |
| Relative Strength Index (RSI) | 59.79 |
| Average Volume (20 Days) | 794,586 |
Short Selling Information
The latest short interest is 2.74 million, so 2.67% of the outstanding shares have been sold short.
| Short Interest | 2.74M |
| Short Previous Month | 3.15M |
| Short % of Shares Out | 2.67% |
| Short % of Float | 2.78% |
| Short Ratio (days to cover) | 2.42 |
Income Statement
In the last 12 months, REGN had revenue of $14.25 billion and earned $4.58 billion in profits. Earnings per share was $41.59.
| Revenue | 14.25B |
| Gross Profit | 6.53B |
| Operating Income | 3.82B |
| Pretax Income | 5.15B |
| Net Income | 4.58B |
| EBITDA | 4.35B |
| EBIT | 3.82B |
| Earnings Per Share (EPS) | $41.59 |
Balance Sheet
The company has $8.44 billion in cash and $2.71 billion in debt, giving a net cash position of $16.02 billion or $156.18 per share.
| Cash & Cash Equivalents | 8.44B |
| Total Debt | 2.71B |
| Net Cash | 16.02B |
| Net Cash Per Share | $156.18 |
| Equity (Book Value) | 30.96B |
| Book Value Per Share | 301.15 |
| Working Capital | 13.56B |
Cash Flow
In the last 12 months, operating cash flow was $5.07 billion and capital expenditures -$849.30 million, giving a free cash flow of $4.22 billion.
| Operating Cash Flow | 5.07B |
| Capital Expenditures | -849.30M |
| Free Cash Flow | 4.22B |
| FCF Per Share | $41.15 |
Margins
Gross margin is 45.83%, with operating and profit margins of 26.83% and 32.13%.
| Gross Margin | 45.83% |
| Operating Margin | 26.83% |
| Pretax Margin | 36.11% |
| Profit Margin | 32.13% |
| EBITDA Margin | 30.52% |
| EBIT Margin | 26.83% |
| FCF Margin | 29.63% |
Dividends & Yields
This stock pays an annual dividend of $3.52, which amounts to a dividend yield of 0.45%.
| Dividend Per Share | $3.52 |
| Dividend Yield | 0.45% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 8.46% |
| Buyback Yield | 4.39% |
| Shareholder Yield | 4.84% |
| Earnings Yield | 5.78% |
| FCF Yield | 5.33% |
Analyst Forecast
The average price target for REGN is $795.74, which is 2.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $795.74 |
| Price Target Difference | 2.54% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 5.88% |
| EPS Growth Forecast (5Y) | 9.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 6.89 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.89 |
| Piotroski F-Score | 4 |